OBJECTIVE: To investigate the effects of Shenqi Yangxin decoction(SQYXD) on heart function in a rat model of dilated cardiomyopathy(DCM) and its potential mechanisms.METHODS: Sprague-Dawley rats were randomly divided ...OBJECTIVE: To investigate the effects of Shenqi Yangxin decoction(SQYXD) on heart function in a rat model of dilated cardiomyopathy(DCM) and its potential mechanisms.METHODS: Sprague-Dawley rats were randomly divided into normal(10 rats) and DCM(150 rats)groups. DCM was induced by an intraperitoneal injection of adriamycin. Then, DCM baseline group was randomly selected sixteen DCM rats. The remaining DCM rats were randomly divided into DCM control, perindopril, metoprolol, and SQYXD groups. Cardiac function and histological analysis plus biochemical measurement of serum levels of brain natriuretic peptide(BNP), and inflammatory factors were measured. The mRNA and protein expression levels of high-mobility group box 1(HMGB1), Toll-like receptor 4(TLR-4), receptor for advanced glycation end products(RAGE), and nuclear factor-κB(NF-κB) were determined. Myocardial metabolism imaging was performed on the normal, SQYXD and DCM control groups to evaluate the effectiveness of treatments.RESULTS: Rats in the DCM control group exhibited dilated left ventricular diameter, impaired cardiac function, disorganized sarcomere, impaired glucose metabolism, increased heart weight index,and increased levels of BNP, which were improved by treatment with SQYXD. In addition, hearts from rats in the DCM baseline group exhibited significantly higher levels of HMGB1, TLR-4, RAGE, NF-κB,tumor necrosis factor-α, interleukin-1, interleukin-6, interleukin-10, compared with the normal group. Interestingly, the mRNA level of HMGB1 in the DCM baseline group was positively correlated with that of TLR-4, RAGE, NF-κB, BNP, and LVEDD,but negatively correlated with LVEF. SQYXD inhibited the upregulation of HMGB1 expression and its downstream inflammatory factors.CONCLUSION: Shenqi Yangxin decoction effectively reduced the dilated left ventricular diameter and improved heart function in dilated cardiomyopathy. The mechanisms underlying the action on DCM involve regulating the gene and protein expression of HMGB1 and its inflammatory signal pathways in the DCM rat model.展开更多
OBJECTIVE: To evaluate the therapeutic effect of Yiqi Yangyin prescription for dilated cardiomyopathy(DCM).METHODS: Electronic databases were searched for relevant clinical randomized controlled trials of DCM treatmen...OBJECTIVE: To evaluate the therapeutic effect of Yiqi Yangyin prescription for dilated cardiomyopathy(DCM).METHODS: Electronic databases were searched for relevant clinical randomized controlled trials of DCM treatment using Yiqi Yangyin prescription(Shengmai and Zhigancao decoction). Databases searched included Pub Med, EMBASE, the Cochrane Library, China National Knowledge Infrastructure Database, Wanfang Database, China Science and Technology Journal Database, and Chinese Biological Medicine from January 1, 1985, to October 31,2015. After literature screening and data extraction according to previously determined exclusion criteria, data were analyzed using Rev Man 5.3 and Stata12.0. Study heterogeneity was evaluated using the I2 test and Cochran's Q test. Egger's test was used to detect publication bias.RESULTS: Nineteen trials involving 1024 partici-pants were included in the Meta-analysis. Of these,15 used Shengmai(treatment group: 421 cases;control group: 344 cases) and 4 used Zhigancao decoction(treatment group: 133 cases; control group:126 cases). A Meta-analysis demonstrated that the total curative effect was significantly improved by combining Shengmai with conventional treatment[relative risk(RR) = 1.32, 95% confidence intervals(CI)(1.22, 1.43), P < 0.01]. Left ventricular ejection fraction [standard mean difference(SMD) = 1.13,95% CI(0.55, 1.70), P < 0.01] and left ventricular end diastolic [SMD =-0.46, 95% CI(-0.70,-0.23), P <0.01] were also improved. Adding Zhigancao decoction achieved the same effect [total efficiency of RR = 1.34, 95% CI(1.16, 1.54), P < 0.01].CONCLUSION: Compared with conventional therapy, Yiqi Yangyin prescription can significantly improve the curative effect, increase left ventricular ejection fraction, and reduce left ventricular end diastolic. Thus, it can effectively improve heart function in patients with DCM.展开更多
基金Supported by the Projects of Medical Technology of Management Center of Wuxi Hospital,Jiangsu Province(No.YGZXM14047:Application of Standardized Diagnosis and Treatment Scheme for Dilated Cardiomyopathy Combined with Staging)the Projects of Jiangsu Province Chinese Medicine Leading Personnel Training Target Fund(Treatment of Dilated Cardiomyopathy with Classic Compound)
文摘OBJECTIVE: To investigate the effects of Shenqi Yangxin decoction(SQYXD) on heart function in a rat model of dilated cardiomyopathy(DCM) and its potential mechanisms.METHODS: Sprague-Dawley rats were randomly divided into normal(10 rats) and DCM(150 rats)groups. DCM was induced by an intraperitoneal injection of adriamycin. Then, DCM baseline group was randomly selected sixteen DCM rats. The remaining DCM rats were randomly divided into DCM control, perindopril, metoprolol, and SQYXD groups. Cardiac function and histological analysis plus biochemical measurement of serum levels of brain natriuretic peptide(BNP), and inflammatory factors were measured. The mRNA and protein expression levels of high-mobility group box 1(HMGB1), Toll-like receptor 4(TLR-4), receptor for advanced glycation end products(RAGE), and nuclear factor-κB(NF-κB) were determined. Myocardial metabolism imaging was performed on the normal, SQYXD and DCM control groups to evaluate the effectiveness of treatments.RESULTS: Rats in the DCM control group exhibited dilated left ventricular diameter, impaired cardiac function, disorganized sarcomere, impaired glucose metabolism, increased heart weight index,and increased levels of BNP, which were improved by treatment with SQYXD. In addition, hearts from rats in the DCM baseline group exhibited significantly higher levels of HMGB1, TLR-4, RAGE, NF-κB,tumor necrosis factor-α, interleukin-1, interleukin-6, interleukin-10, compared with the normal group. Interestingly, the mRNA level of HMGB1 in the DCM baseline group was positively correlated with that of TLR-4, RAGE, NF-κB, BNP, and LVEDD,but negatively correlated with LVEF. SQYXD inhibited the upregulation of HMGB1 expression and its downstream inflammatory factors.CONCLUSION: Shenqi Yangxin decoction effectively reduced the dilated left ventricular diameter and improved heart function in dilated cardiomyopathy. The mechanisms underlying the action on DCM involve regulating the gene and protein expression of HMGB1 and its inflammatory signal pathways in the DCM rat model.
基金Supported by Research Project of Wuxi Hospital Management Center(Comparative Study on the Effect of Yiqi Yangyin Prescription for Treatment of Autoimmune Myocarditis and Immunity Regulation Mechanism,No.YGZXM1526)
文摘OBJECTIVE: To evaluate the therapeutic effect of Yiqi Yangyin prescription for dilated cardiomyopathy(DCM).METHODS: Electronic databases were searched for relevant clinical randomized controlled trials of DCM treatment using Yiqi Yangyin prescription(Shengmai and Zhigancao decoction). Databases searched included Pub Med, EMBASE, the Cochrane Library, China National Knowledge Infrastructure Database, Wanfang Database, China Science and Technology Journal Database, and Chinese Biological Medicine from January 1, 1985, to October 31,2015. After literature screening and data extraction according to previously determined exclusion criteria, data were analyzed using Rev Man 5.3 and Stata12.0. Study heterogeneity was evaluated using the I2 test and Cochran's Q test. Egger's test was used to detect publication bias.RESULTS: Nineteen trials involving 1024 partici-pants were included in the Meta-analysis. Of these,15 used Shengmai(treatment group: 421 cases;control group: 344 cases) and 4 used Zhigancao decoction(treatment group: 133 cases; control group:126 cases). A Meta-analysis demonstrated that the total curative effect was significantly improved by combining Shengmai with conventional treatment[relative risk(RR) = 1.32, 95% confidence intervals(CI)(1.22, 1.43), P < 0.01]. Left ventricular ejection fraction [standard mean difference(SMD) = 1.13,95% CI(0.55, 1.70), P < 0.01] and left ventricular end diastolic [SMD =-0.46, 95% CI(-0.70,-0.23), P <0.01] were also improved. Adding Zhigancao decoction achieved the same effect [total efficiency of RR = 1.34, 95% CI(1.16, 1.54), P < 0.01].CONCLUSION: Compared with conventional therapy, Yiqi Yangyin prescription can significantly improve the curative effect, increase left ventricular ejection fraction, and reduce left ventricular end diastolic. Thus, it can effectively improve heart function in patients with DCM.
